Advertisement
UK markets close in 59 minutes
  • FTSE 100

    8,387.92
    +33.87 (+0.41%)
     
  • FTSE 250

    20,546.78
    +54.79 (+0.27%)
     
  • AIM

    782.82
    +2.99 (+0.38%)
     
  • GBP/EUR

    1.1610
    -0.0012 (-0.11%)
     
  • GBP/USD

    1.2513
    +0.0016 (+0.13%)
     
  • Bitcoin GBP

    48,934.12
    -1,027.80 (-2.06%)
     
  • CMC Crypto 200

    1,322.85
    +22.75 (+1.75%)
     
  • S&P 500

    5,198.02
    +10.35 (+0.20%)
     
  • DOW

    39,229.81
    +173.42 (+0.44%)
     
  • CRUDE OIL

    79.44
    +0.45 (+0.57%)
     
  • GOLD FUTURES

    2,343.70
    +21.40 (+0.92%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • HANG SENG

    18,537.81
    +223.95 (+1.22%)
     
  • DAX

    18,676.60
    +178.22 (+0.96%)
     
  • CAC 40

    8,183.60
    +52.19 (+0.64%)
     

Valeant Pharmaceuticals’ Baush & Lomb in 4Q17 and 2017

Valeant Pharmaceuticals’ Baush & Lomb in 4Q17 and 2017

In 4Q17, Valeant Pharmaceuticals’ (VRX) subsidiary Bausch & Lomb reported revenues of $1.2 billion compared to $1.3 billion in 4Q16. That was a 3% growth on a YoY (year-over-year) basis and a 2% growth quarter-over-quarter.